Radiofrequency Ablation of Subpleural Lung Malignancy: Reduced Pain Using an Artificially Created Pneumothorax by Lee, Edward W. et al.
CASE REPORT
Radiofrequency Ablation of Subpleural Lung Malignancy:
Reduced Pain Using an Artiﬁcially Created Pneumothorax
Edward W. Lee Æ Robert D. Suh Æ Michelle R. Zeidler Æ
Irene S. Tsai Æ Robert B. Cameron Æ
Fereidoun G. Abtin Æ Jonathan G. Goldin
Received: 5 August 2008/Accepted: 8 January 2009/Published online: 5 February 2009
 The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract One of the main issues with radiofrequency
(RF) ablation of the subpleural lung malignancy is pain
management during and after RF ablation. In this article,
we present a case that utilized a technique to decrease the
pain associated with RF ablation of a malignancy located
within the subpleural lung. Under CT guidance, we created
an artiﬁcial pneumothorax prior to the RF ablation, which
resulted in minimizing the pain usually experienced during
and after the procedure. It also decreased the amount of
pain medications usually used in patients undergoing RF
ablation of a subpleural lung lesion.
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Introduction
Percutaneous radiofrequency (RF) ablation is a minimally
invasive and nonsurgical technique used to treat various
solid tumors. Many studies have shown that this technique
is safe and effective in treating hepatic and renal tumors
[1–3]. Recent investigations of RF ablation’s practicability
and outcome as a successful method for extricating primary
and metastatic lung tumors have been promising [4–8].
Studies have shown that RF ablation is evolving into a
suitable alternative and adjuvant method to open thoracic
surgery of primary and metastatic lung cancer, which is
commonly associated with high morbidity and mortality [9,
10]. However, there are many issues concerning RF abla-
tion that need to be addressed. These questions mainly
involve patient selection, location and type of lung
malignancy, accessibility of the lesion, possible risks for
acute and chronic complications and management, and
ﬁnally, pain management, both during and after the RF
ablation [11]. In this article, we present a case that utilized
a technique to decrease the pain associated with RF abla-
tion of a malignancy located within the subpleural lung.
Under CT guidance, we created an artiﬁcial pneumothorax
prior to the RF ablation, which resulted in minimizing the
pain usually experienced during and after the procedure.
Case Report
The patient’s written informed consent was obtained after
the risk, beneﬁts, and alternatives of the procedure were
fully explained. A waiver of informed consent was
obtained from the IRB for this report.
A 43-year-old woman with a history of metastatic
colorectal cancer to the liver, originally diagnosed in 1999,
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(CEA), and CT scan of the chest conﬁrmed the develop-
ment of three new subcentimeter nodules within both
lungs. These nodules were consistent with pulmonary
parenchymal metastases: one within the right middle lobe
and, notably, two nodules within the anterior segment of
the left upper lobe, one within the subpleural aspect of the
lobe (Fig. 1A) and the other central. Due to slow pro-
gression of the tumor within the lung, complications of
hypercoagulability related to the patient’s current systemic
chemotherapy and her prior familiarity with RF ablation
for at least three hepatic metastases, RF ablation was pre-
ferred over surgical metastasectomy.
The patient was prepped and draped in sterile fashion,
and midazolam hydrochlorate (1 mg of Versed; Roche
Laboratories, Nutley, NJ, USA), fentanyl citrate (25 lgo f
Sublimaze; Akorn, Buffalo Grove, IL, USA), and diphen-
hydramine hydrochloride (25 mg of Benadryl; Pﬁzer Inc.,
New London, CT, USA) were administered intravenously
to induce moderate sedation. Utilizing the GE HiSpeed
Advantage CT Scanner (GE Medical Systems, Milwaukee,
WI, USA) with the patient in the supine position, a 22-
gauge Chiba needle (Cook, Bloomington, IN, USA) was
placed adjacent to the peripherally located metastasis
within the anterior segment of the left upper lobe via
anterior intercostal approach (Fig. 1A). Following CT
conﬁrmation of the needle tip, a RITA 6.4-Fr Starburst-XL
multiarray electrode (RITA Medical Systems, Mountain
View, CA, USA) was placed so that its leading tip was
situated to enter proximally into the parietal and visceral
pleura and the underlying lung.
Based on results by others using iatrogenic pneumo-
thorax for easy access to a tumor [12–14], we deduced that
iatrogenic pneumothorax may decrease pain by separating
the two pleural layers or the visceral from the somatically
innervated parietal pleura. With slow and deliberate tine
deployment to 3 cm, an intentional and iatrogenic artiﬁcial
pneumothorax was created, the tines of the electrode
piercing the lung and surrounding the targeted nodule,
while displacing the visceral pleura away from the parietal
pleura (Fig. 1B). In order to further enlarge the potential
pneumothorax, the deployed electrode was then advanced,
ensuring that its 1-cm active tip was entirely within the
pleural space and pneumothorax (Fig. 1C). Subsequently, a
single RF ablation was performed according to the manu-
facturer’s guide (Fig. 1C). By separating the visceral and
somatically innervated parietal pleura with a potential
space, we observed very minimal patient discomfort during
the ablation session. In addition, we were still able to
achieve effective capture of the targeted nodule within the
expanded array, without negatively affecting the patient’s
oxygen saturation and vital signs. Following completion of
the ablation, the tines were retracted with the electrode tip
still residing within the pleural space and pneumothorax.
With a 20-ml Luer lock syringe attached to the side port of
the electrode, the RF electrode was withdrawn with nega-
tive suction applied to the syringe, thereby manually
decompressing the associated localized pneumothorax and
actively aspirating any potential air leak (Fig. 1D). The
second nodule was then localized with the Chiba needle,
and via tandem needle technique, the Starburst electrode
was driven to the nodule, its tines deployed, and the
metastasis ablated using standard technique. Due to the
second nodule’s more central location, repeat creation of
an artiﬁcial pneumothorax was not performed. Before RF
ablation, as the Chiba needle was removed, 2 ml of
Fig. 1 Sequential CT images of radiofrequency ablation of subpleu-
ral tumor. A A 22-gauge Chiba needle was placed adjacent to the
peripherally located metastasis (white arrowhead: subpleural tumor).
B An intentional and iatrogenic artiﬁcial pneumothorax was created
displacing the visceral pleura (white arrows: artiﬁcial pneumothorax).
C Enlargement of the artiﬁcially created pneumothorax further
separated the ablation site from the parietal pleura. D Following
completion of the ablation, the tines were retracted and a localized
pneumothorax was decompressed by active aspiration using a syringe
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Intraprocedural CT scans of the thorax showed no air
within the pleural cavity following the ﬁrst ablation and a
minimally sized residual pneumothorax following the
second ablation, which required no subsequent intervention
or further treatment. The overall procedure time was not
signiﬁcantly different from that for the conventional
method. Postablation CT images demonstrated progressive
ground-glass attenuation envelopment of each targeted
nodule, suggestive of a successful RF ablation. Throughout
the RF ablation procedure and postprocedure observation
period, the patient’s vital signs, including oxygen satura-
tion, remained stable. Following the procedure, the patient
did not require any additional analgesia or narcotics for
pain control. The patient was discharged on the same day
with minimal oral NSAID for pain control.
Nine-month follow-up CT images demonstrated dense
bands of scarring with signs of shrinkage of ablation-
induced areas of necrosis, as well as complete resolution of
the pneumothorax.
Discussion
RF ablation is a minimally invasive and effective method
used to treat various tumors by inducing complete coagu-
lation necrosis and cell death of a targeted tumor, with
generally few complications. The physiological heat insu-
lation created by air surrounding the tumor produces more
effective thermal energy for complete cell necrosis [15];
therefore, RF ablation is thought to be a suitable treatment
option for pulmonary malignancy. However, the literature
on the percutaneous ablation of thoracic tumors, although
expanding, is still incomplete, and multiple technical issues
require address and optimization.
One issue that has been a constant challenge for RF
operators has been patient pain management. For the most
part, RF ablation has been performed as an outpatient
procedure, usually under moderate sedation. Operators
have at times favored deep sedation and even general
anesthesia, particularly in patients with targeted lesions
involving the pleura and/or chest wall, and especially in
those seeking palliation for pain. RF ablation-induced pain
causes discomfort and agitation for patients during and
following the procedure. It can cause a wide spectrum of
pain ranging from tolerably mild pain to severe pain
requiring high doses of narcotics or sedatives, or even
general anesthesia, which necessitates anesthesiology ser-
vice. One study has shown that RF ablation-induced pain is
the second most frequently cited complication of the RF
ablation procedure, requiring general anesthesia at their
institution [16]. In particular, RF ablation involving the
pleural margin, as in our case, has been known to cause
more severe pain, usually requiring multiple intercostal
nerve blocks or general anesthesia to proceed with the
procedure [11, 17].
The consequences of RF ablation-induced pain can
present additional problematic issues. With severe intra-
ablational pain and its management, subsequent electrode
repositioning for overlapping ablations required in larger
tumor therapy may be jeopardized, in that a higher and
deeper level of moderate sedation and pain control during
the procedure will diminish lung aeration and expansion
and patient cooperation. The technical difﬁculties
encountered in repeated electrode repositioning and
deployment may overly lengthen the procedure and induce
additional complications, especially in those patients with
advanced lung diseases and poor pulmonary reserve,
leading to difﬁcult and prolonged recovery.
With prolonged postprocedural pain, patients may splint
and limit their respiratory excursion. With decreased lung
ventilation and clearance function, the possibility of
infection rises within the suboptimally aerated lung. In
general, RF ablation-induced pain reduces the beneﬁts of
the noninvasiveness of RF ablation and may cause rela-
tively extended care and potential hospitalization for post-
RF ablation pain control. Therefore, the procedure may
become less cost-effective and less attractive as an alter-
native therapeutic method to surgery.
As previously mentioned, RF ablation of tumors
involving the pleural margin is known to incite more pain
sensors than others [11]. However, our case presentation
has suggested that an artiﬁcially created pneumothorax
may mitigate the pain for those patients undergoing RF
ablation of those types of tumors. In our patient, the
amount of sedation (25 lg of fentanyl and 1 mg of
midazolam) used was substantially less than what is usu-
ally required (200 lg of fentanyl and 3 mg of midazolam)
in our experience. In fact, this technique does not require
general anesthesia or intercostal nerve block. Despite cre-
ation of a pneumothorax, the overall procedure time was
not signiﬁcantly increased, since the pneumothorax was
established as the electrode was inserted and not before-
hand. Overall, complications related to intraprocedural
pain and deep sedation are minimized, potentially with
better outcomes than with the other conventional methods
of treating subpleural tumors. Although our case may
suggest beneﬁts of using iatrogenic pneumothorax to
reduce the pain, possible risks and limitation must be
evaluated. No major unpredicted complications are
expected other than the usual potential complications that
RF ablation of the lung may cause. However, a larger than
planned pneumothorax or a pneumothorax related to an
actual air leak may be anticipated. This may cause respi-
ratory distress, but immediate awareness and treatment
should minimize further deleterious respiratory
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123deterioration. There are reports of utilizing artiﬁcially
created pneumothorax to reach tumors in other target
organs, such as the upper pole of the kidney [12], the
hepatic dome [13], and the mediastinum/pulmonary hilum
[14] to prevent traversal of aerated lung parenchyma.
However, this is one of the ﬁrst observations of utilizing an
artiﬁcial pneumothorax to reduce RF ablation-induced pain
in ablation of an intrathoracic intrapulmonary subpleural
tumor. Future investigation focused on followings will be
useful to potentiate the pain-reducing effect of iatrogenic
pneumothorax in lung RF ablation: (i) evaluating a cohort
of patients utilizing a subjective and objective pain scale,
both during and after the procedure; and (ii) investigating
how reproducible and feasible this technique is in different
clinical settings such as patients with a history of lung/
pleural surgery with scarring or patients with emphyse-
matous disease.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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